PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31433581-9	2019	RESULTS: Epirubicin inhibited proliferation in a dose-dependent manner, induced apoptosis, decreased the expression of Bcl-2, and increased the expressions of Bax, cleaved-caspase-3, and cleaved-PARP1 in osteosarcoma cells.	Epirubicin	9-19	BCL2 apoptosis regulator	Homo sapiens	119-124	
32357825-12	2020	CONCLUSION: Epirubicin induced apoptosis in human bladder cancer cells by up-regulating the expression of pro-apoptotic factors (caspase-3, p53 and Bax) and down-regulating the expression of anti-apoptotic factor (Bcl-2).	Epirubicin	12-22	BCL2 apoptosis regulator	Homo sapiens	214-219	
32357825-10	2020	The expression of caspase-3, p53 and Bax were increased and the expression of Bcl2 was decreased with epirubicin treatment on human bladder cells, which were analyzed by western blot.	Epirubicin	102-112	BCL2 apoptosis regulator	Homo sapiens	78-82	
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	BCL2 apoptosis regulator	Homo sapiens	204-209	
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	BCL2 apoptosis regulator	Homo sapiens	108-113	
28968471-10	2017	The combined treatments of siHuR and epirubicin significantly reduced the expression of Bcl-2, but increased the expression of Bax, as well as activity and expression levels of caspase-3 and -9.	Epirubicin	37-47	BCL2 apoptosis regulator	Homo sapiens	88-93	
22340335-0	2011	Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.	Epirubicin	45-55	BCL2 apoptosis regulator	Homo sapiens	14-19	
22340335-9	2011	A marked down-regulation of Bcl-2 mRNA and protein was observed after antisense and epirubicin cotreatment.	Epirubicin	84-94	BCL2 apoptosis regulator	Homo sapiens	28-33	
22340335-10	2011	A statistically significantly higher fraction of apoptotic cells was detected by flow-cytometric analysis after epirubicin treatment with prior antisense Bcl-2 transfenction, as compared with mono antisense Bcl-2 or epirubicin treatment.	Epirubicin	112-122	BCL2 apoptosis regulator	Homo sapiens	154-159	
21906442-5	2011	The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.	Epirubicin	97-107	BCL2 apoptosis regulator	Homo sapiens	52-57	
21906442-6	2011	CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2.	Epirubicin	12-22	BCL2 apoptosis regulator	Homo sapiens	130-135	
30304783-5	2018	We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax.	Epirubicin	58-68	BCL2 apoptosis regulator	Homo sapiens	111-116	
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	BCL2 apoptosis regulator	Homo sapiens	200-205	
27609577-6	2016	After the cells were treated with 0.5 mg/L(IC50) epirubicin, the apoptosis rate of MGC-803 cells was raised, the protein expressions of caspase-3 , caspase-9 and Bax were significantly upregulated and Bcl-2 was downregulated.	Epirubicin	49-59	BCL2 apoptosis regulator	Homo sapiens	201-206	
24637737-8	2014	Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2.	Epirubicin	0-10	BCL2 apoptosis regulator	Homo sapiens	118-123	
24637737-10	2014	The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study.	Epirubicin	19-29	BCL2 apoptosis regulator	Homo sapiens	120-125	
19000447-12	2008	The inhibition rates of 5-fluorouracil (5-FU), VCR, epirubicin (EADM) and OXA on cancer cells were lower in the group with strong expression of bcl-2 than in that with weak expression of bcl-2 (P<0.05).	Epirubicin	52-62	BCL2 apoptosis regulator	Homo sapiens	144-149	
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	BCL2 apoptosis regulator	Homo sapiens	286-291	
16965675-12	2006	Co-treatment with troglitazone and epirubicin further downregulated the expression level of Bcl-2 and inhibited cell migration simultaneously.	Epirubicin	35-45	BCL2 apoptosis regulator	Homo sapiens	92-97	
16109560-1	2005	OBJECTIVE: To observe the expression of Bcl-2 and Bax proteins and cell apoptosis induced by preoperative lymphatic chemotherapy with epirubicin-activated carbon suspension (Epi-CH) in the cells of axillary metastatic lymph node of breast cancer and investigate the mechanism.	Epirubicin	134-144	BCL2 apoptosis regulator	Homo sapiens	40-45